1. Moreira PL, Lansden CC, Clark TL. Effect of Hemopure® on prothrombin time and activated partial thromboplastin time on seven coagulation analyzers. Clin Chem. 1997;43:1792.
2. Mischke R, Wolling H. Influence of fibrinogen degradation products on thrombin time, activated partial thromboplastin time and prothrombin time of canine plasma. Haemostasis. 2000;30:123–30.
3. Mischke R, Menzel D, Wolling H. Comparison of different methods to measure fibrinogen concentration in canine plasma with respect to their sensitivity towards the fibrinogen degradation products X, Y and D. Haemostasis. 2000;30:131–8.
4. Point-of-care monitoring of anticoagulation therapy; approved guideline. CLSI document H49-A. Wayne: Clinical and Laboratory Standards Institute; 2004.
5. Remijn JA, Wildeboer B, van Suijlen JDE, Adriaansen HJ. Recombinant thromboplastins vs tissue-extract thromboplastins in patients on unstable oral anticoagulant therapy. Clin Chem. 2011;57:916–7.